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enable the use of multiple modalities and achieve depth-resolved whole-body tracking of immunomarkers 
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Dynamic immunoimaging in vivo is critical in patient-tailored immunotherapies to identify the 
patients who will benefit from immunotherapies, to monitor therapeutic efficacy post-treatment, 
and to determine alternative strategies for nonresponders.  Nanoparticles have played a major role 
in the immunotherapy landscape. In this review we summarize the recent findings in 
immunoimaging where smart nanoparticles target, detect, stimulate, and deliver therapeutic dose 
in vivo.  Nanoparticles interfaced with immunoimaging toolbox enable the use of multiple 
modalities and achieve depth-resolved whole body tracking of immunomarkers with high accuracy 
before and after treatment.  Distinct from other reviews, we highlight for the first time how 
functional nanoparticles track T cells, dendritic cells, tumor-associated macrophages, and immune 
checkpoint receptors, and facilitate image-guided interventions.    
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 Enhanced permeability and retention (EPR) effect: EPR effect allows macromolecules and 
nanoparticles to accumulate in the tumor interstitial spaces due to the leaky tumor 
vasculatures and the lack of lymphatic drainage system.  
 
 Tumor microenvironment (TME): TME describes the mass surrounding cancer cells, 
including extracellular matrix, stromal cells, immune cells and the tumor vasculatures.  
 
 Mononuclear phagocyte system (MPS): MPS system refers to the phagocytic cells, 
primarily splenic macrophages, Kupffer cells in the liver and the monocytes that are located 
in reticular connected tissues.   
 
 Dendritic cells (DCs): DCs are professional antigen presenting cells that capture, process 
and present neoantigens to T cells.  DCs play an important role in bridging adaptive and 
innate immune system.  
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 T cells: T cells are lymphocytes that play a central role in adaptive immune system in 
defending against both intracellular and extracellular pathogens.  For example, in adoptive 
T cell therapy, healthy T cells are systemically delivered in cancer patients to build a 
stronger immune system and fight against cancer. 
 
 Tumor associated macrophages (TAMs): TAMs are macrophages that promote tumor 
progression and immunosuppressive TME by producing cytokine and chemokines. 
 
 Immune checkpoint receptors (ICRs): ICRs are regulatory receptors in the immune system 
that maintain self-tolerance. Upregulation of ICRs in cancer allows tumors to evade 
immune surveillance.  Blockades of ICRs with therapeutic antibodies have recently shown 
to significantly improve clinical outcome in cancer patients.  
 
 Positron Emission Tomography (PET) imaging: PET imaging is a nuclear imaging 
technique that detects the annihilations of photons from the positron emitting radionuclide.  
PET provides sensitive three-dimensional results and is often used to monitor metabolic 
changes in TME.  
 
 Raman Spectroscopy: Raman spectroscopy measures the characteristic vibrational states, 
including bending, stretching and rotational modes of molecules.  Raman spectroscopy is 
highly specific to the composition of the molecule being probed, and therefore useful for 
high resolution dynamic imaging in vivo. 
 
 Computed Tomography (CT): CT tomography provides more detailed information of soft 
tissue, bones and vasculatures than conventional x-ray images by combining multiple 
cross-sectional images of the body acquiring from different angles. 
 
 Magnetic Resonance Imaging (MRI): MRI imaging is a non-invasive clinical diagnostic 
and treatment monitoring technique that utilizes magnetic field and radio waves to produce 
three-dimensional images and great anatomical details.  
 
 Fluorescence Imaging: Fluorescence imaging visualizes fluorescent dyes that are attached 




Emerging Need for Immunoimaging 
Cancer immunotherapies including blockade of immune checkpoint receptors (ICRs), 
adoptive T cell therapy (ACT), and vaccine delivery have recently driven a paradigm shift in 
patient survival.  Dynamic molecular imaging of immune cells and markers has transformed our 
ability to understand innate and adaptive immune responses in the pathogenesis of cancer [1, 2].  
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This transformation is in part motivated by the failure of conventional imaging and histopathology 
to accurately predict response to immunoagents in a clinical setting.  For traditional cancer 
therapies, evaluation of treatment response is based on the reduction of tumor size, and the absence 
of new tumors in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) 
[3].  However, in immunotherapies, pseudoprogression has emerged as a distinct response pattern, 
where activated immune cells infiltrating the tumor milieu elicit an increase in tumor volume and 
a delayed treatment response [4, 5].  Therefore, immunoimaging is indispensable to assess changes 
in tumor burden, allow early therapeutic intervention, reflect dynamic changes in immunomarkers 
during immunotherapies, and avoid premature termination of effective treatment based on 
RECIST criteria.   
Immune cells including T cells, dendritic cells (DCs) and tumor associated macrophages 
(TAMs) and ICRs are critical in maintaining immune surveillance and in cancer immunotherapies.  
T cells are an important effector of the immune system and are critical for inhibition of tumor 
growth, invasion, and metastasis.  In the past decade, ACT have demonstrated remarkable success 
in remission-free survival of patients necessitating accurate imaging of T cells in vivo for both 
planning of ACT and for monitoring treatment response.  DCs are professional antigen presenting 
cells that link the innate and adaptive responses of the immune system.  However, DCs-based 
therapeutic vaccines lack efficient migration into targeted peripheral lymph nodes (LNs).  
Noninvasive tracking of DC migration in vivo is therefore imperative for targeted delivery of 
vaccines, and has been enabled by DCs labeled with smart nanoparticles (SNPs).  TAMs are 
immune cells that drive an immunosuppressive tumor microenvironment (TME) and promote 
metastasis.  Immunotherapy strategies that either suppress pro-tumor M2 phenotype TAMs or 
reprogram them to an antitumor M1 phenotype have gained tremendous momentum [6, 7].  
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However, success of these therapies relies on quantifying the distribution of TAMs in the TME 
with high resolution imaging facilitated with SNPs.  In addition to immune cells, ICRs such as 
programmed cell death 1 (PD-1), which are negative costimulatory molecules, are overexpressed 
on cytotoxic T lymphocytes (CTLs).  Upregulation of ICRs impedes T cell activation and enables 
tumors to evade immune surveillance [8-10].  Immunotherapies blocking ICRs have shown 
tremendous promise in clinical trials among many tumor types, but ~75% cancer patients currently 
do not respond to this regimen in part due to poor prediction of ICRs in tumors [11-13].  Real-time 
tracking of ICR distribution before, during, and after ICR blockade therapies is highly desirable to 
ultimately improve patient-tailored immunotherapies.   
 
 
Figure 1. Schematic of design considerations for smart nanoparticles including size, shape, surface 
charge, material composition, and stiffness integrated with appropriate labels to enable imaging of 
immune cells and immunomarkers for image-guided immunotherapies. Glossary: polyethylene 
glycol (PEG), gold nanoparticles (Au NPs), superparamagnetic iron oxide (SPIO), dendritic cells 




Design Considerations of Smart Nanoparticles for Immunoimaging  
The emerging need to accurately image the immune TME has led to an unmet clinical need 
for safe, biocompatible, and multifunctional SNPs that enable us to diagnose patients who will 
respond to immunotherapies even before treatment begins.  Further, SNPs also provide an early 
response to therapy improving the treatment outcome of responders, accelerate clinical decisions 
for those requiring alternative therapies, and minimize toxicities and high costs of unsuccessful 
treatment for those identified as nonresponders.  An expansive list of NP-based detection of 
various immune cells and the corresponding imaging toolbox employed is shown in Table 1.  
However, there are key design considerations of SNPs including their size, shape, surface 
properties, and composition that need to be evaluated for their utility in the TME (Fig.1).  These 
design parameters of SNPs govern their biodistribution and clearance in vivo and ability to track 
immunomarkers.  Size of SNPs is of foremost importance as NPs <10 nm undergo rapid renal 
clearance, whereas those >200 nm have heterogeneous distribution in the TME due to poor 
enhanced permeability and retention (EPR) effect [14].  This size-dependent glomerular filtration 
cut-off was established by quantifying the glomerular sieving coefficient (θ) (the ratio of urine 
amount to plasma amount) of NPs, where θ approaches 1 when Stokes-Einstein radius (r) is ~1 nm 
and θ decreases to ~0 if r >5 nm [15].  However, this cut-off is smaller for rigid NPs that do not 
deform easily.  SNP size is also crucial for penetration into solid tumors, where SNPs >10 nm only 
enter via interendothelial cell gaps across the blood vessel walls.  But SNPs <10 nm extravasate 
from normal capillaries that also have intercellular gaps resulting in deep tumor penetration [16].  
A recent study showed 2 nm and 6 nm gold nanoparticles (AuNPs) penetrate necrotic regions of 
the tumor that are defined by poor vasculature and oxygen levels in both tumor spheroids and in 
vivo.  However, 15 nm AuNPs remain in the outer layers of the TME with sufficient blood and 
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nutrient supply localizing in the angiogenic areas of tumor microvasculars [17].  Whereas most of 
these studies emphasize that SNPs uptake in TME relies on the EPR effect, Leong and co-workers 
have shown SNPs could induce endothelial cell (EC) leakiness (NanoEL) which is correlated to 
the size and surface charge of SNPs [18, 19].  NanoEL is caused by disruption of EC interactions 
by binding to critical adherens junction proteins which exert a disruptive force causing vasculature 
leakiness.  The authors showed 10-30 nm AuNPs induce NanoEL in ECs and improve transport 
of SNPs to the targeted tissue through opening of the paracelullar route, a finding that is essential 
for SNPs accumulation in the immune TME [19].  
 Shape of SNPs is also pivotal for imaging immune cells as transport of flowing SNPs is 
controlled by their margination (i.e. radial drift) towards the blood vessel walls and is controlled 
by SNPs translational and rotational motion.  Multiple forces dictate NP motion, including 
buoyancy, gravity, drag, van der Waals interactions, and steric repulsive interactions.  Under a 
balance of these forces spherical NPs follow a streamlined straight flow, whereas rod-shaped NPs 
experience lateral drift that varies depending on the angle of their orientation.  In addition to these 
forces, SNPs uptake in the TME is also determined by their endocytosis pathway, which is directed 
by the SNPs shape.  Xie and coworkers compared nanostars, nanorods, and nanotriangles and 
showed nanotriangles had the highest uptake in cells driven by uptake via the Dynamin pathway 
[20].  A later study then showed spherical AuNPs were largely membrane-bound with rapid 
cellular excretion via exocytosis, but Au nanostars (AuNSs) were translocated to cytoplasm with 
restricted mobility and suppressed exocytosis rate [21].  We have observed AuNSs support these 
findings, where high uptake was observed in vitro and long circulation times in vivo [22, 23].  
SNPs shape also determines their uptake by macrophages of the mononuclear phagocyte system 
(MPS), where uptake of spherical SNPs is favored over nanorods and nanochains [24, 25].  These 
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findings were supported by a recent work where Oh and colleagues showed high aspect-ratio 
nanorods escape from TAMs enabling their localization in tumors, and are rapidly cleared by the 
liver through efficient Kupffer cell-hepatocyte transfer [26].  Therefore, morphological modulation 
of SNPs is critical to their in vivo fate and their ability to hone in immune cells. 
 The surface charge of SNPs also governs their ability to reach the TME and subsequent 
clearance via the MPS.  Studies show positively charged SNPs accumulate in liver hepatocytes 
while negatively charged SNPs have nonspecific distribution in liver [27].  While cationic SNPs 
demonstrate high cellular uptake since cancer cells have negative surface charge [28], 
immunogenicity and toxicity of charged SNPs have given rise to significant concerns.  The 
simplest approach to minimize SNPs toxicity and uptake by the MPS has been achieved by coating 
polyethylene glycol (PEG), a nontoxic food and drug administration (FDA) approved hydrophilic 
polymer.  PEG coating increases SNPs solubility, overall stability, protease resistance, and in vivo 
half-life, and decreases adsorption of opsonin, a serum protein known to form protein corona, 
which collectively reduces their uptake by macrophages [29].  In an early work, Chan and co-
workers showed that the PEG grafting density controls the adsorption of >70 different serum 
proteins on the surface of AuNPs, where a higher PEG density reduced the total serum protein 
adsorption  [30].  A recent work corroborated these findings by showing that PEG grafting density 
and corresponding PEG conformation (mushroom to brush) control the plasma circulation of SNPs 
in vivo [31].  SNPs with a dense inner (primary) PEG layer thermodynamically prevent serum 
proteins from accessing NPs via steric repulsion, and outer PEG layer (mushroom regime) enables 
topographical stability to kinetically interfere with protein corona formation resulting in long 
circulating SNPs.  These physicochemical properties are not individually responsible for the fate 
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of SNPs in vivo, but entanglement of these design parameters often complicates the prediction of 
the functionality of SNPs [32].   
  The material composition of SNPs has been the driving factor in our ability to track 
immune cells migration with an expansive immunoimaging toolbox (Table 1) and provide 
mechanistic understanding of immunotherapies.  Therefore, this review focuses on three major 
classes of SNPs: AuNPs, superparamagnetic iron oxide nanoparticles (SPIONs), and organic 
NPs categorized by composition.  These SNPs were chosen due to abundant literature findings 
on these classes of material, and each of these material has a unique advantage in terms of shape 
and surface tunability to achieve higher cellular uptake (AuNPs), small size with natural magnetic 
properties for magnetic resonance imaging (MRI) contrast (SPIONs), and ability to combine 
imaging and therapy for image-guided approaches (organic NPs).  We found that the cancer type 
or immune cell type does not dictate success in immunoimaging with SNPs, but how the material 
property allows to control other physicochemical properties and also enable their interaction with 
the immune TME.  Each SNP section discusses the merits of the material and reviews the recent 
progress in immunoimaging correlating to the design consideration discussed here.  
 
Gold Nanoparticles  
AuNPs have been used for two decades as imaging contrast agents and as photothermal 
actuators for light-based therapies and have been successful in humans [33].  The rapid surge of 
AuNP based SNPs for immunoimaging is primarily attributed to their high biocompatibility, 
minimal toxicity, and ease of synthesis that allows to tune their design parameters and 
corresponding near-infrared (NIR) light absorption properties.  Further, Au surface chemistry is 
amenable to straightforward bioconjugation through well-established approaches.  These 
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properties of AuNPs have been leveraged for immunoimaging with contrast-enhanced computed 
tomography (CT), since AuNPs attenuate x-rays and delineate soft tissues.  The X-ray attenuation 
capacity of AuNPs is size-dependent, where a study comparing 4-60 nm AuNPs found that since 
X-ray attenuation depends on the target area, smaller AuNPs with larger surface area have higher 
X-ray attenuation.  Therefore, the 4 nm AuNPs served as the most efficient CT contrast agent in 
their study[34].  In this effort, Meir and coworkers demonstrated that T cells labeled with 20 nm 
glucose-coated AuNPs can be tracked in vivo with CT imaging (Fig. 2a) [35].  Note that T cell 
tracking in vivo can only be achieved if the cells are labeled with AuNPs ex vivo and then 
introduced in mouse models via ACT.  The glucose coating was critical to high stability of AuNPs 
and for enhanced uptake by T cells, since glucose metabolism in lymphocytes drives their growth, 
proliferation, and effector function [36].  Longitudinal CT imaging demonstrated their robust 
approach resulted in migration and honing of T cells in tumors for up to 48 hours post ACT (Fig.2a).  
In another work, the same group also detected programmed cell death-ligand 1 (PD-L1) 
immunomarker via antiPD-L1 conjugated AuNPs which showed higher accumulation in tumors 
relative to control AuNPs conjugated with isotype-matched IgG (Fig.2b) [37].  Depth-resolved CT 
images showed PD-L1 targeted AuNPs achieved better tumor penetration and higher infiltration 
than the control (Fig.2c).  These findings suggest that relying solely on the EPR effect to initiate 
passive accumulation in tumors is ineffective in tumor targeting, and modulating the surface 




Figure 2. Immunoimaging with gold nanoparticles. (a) Glucose modification of AuNPs to 
enable uptake in T cells. (b) PD-L1 conjugated AuNPs targeted B16 tumors with CT imaging. PD-
L1 labelled AuNPs resulted in (c) longitudinal tracking of AuNP labelled T cells with CT imaging 
24-72h post-delivery. (d) Transmission electron micrograph of AuNSs showing their anisotropic 
morphology. (e) Schematic showing mice bearing mammary tumors were systemically 
administered with a mixture of antiEGFR-pMBA-AuNS and antiPD-L1-DTNB-AuNS to detect 
both markers. (f) Ex vivo SERS map of whole tumor lesions shows multiplexed detection of both 
EGFR (green, pMBA 1580 cm-1) and PD-L1 (red, DTNB 1325 cm-1). (g) Zoomed in ex vivo 
Raman maps and corresponding Raman spectra showing areas with (1) no SERS signal (2) PD-
L1-rich tissue, (3) EGFR-rich tissue, and (4) both receptors. (h) Schematic of synthesis of tannic 
acid-coated core shell AuNP were radiolabeled (124I-TA-Au@AuNPs) for (i) tracking bone 
marrow-derived DCs with PET/CT imaging. (a) was adapted with permission from American 
Chemical Society ref. [35], (b) – (c) were adapted with permission from American Chemical 
Society ref. [37], (d) – (g) were adapted with permission from Royal Society of Chemistry ref. 
[22], (i) was adapted with permission from Springer Nature ref. [38], and (h) was adopted with 
permission from American Chemical Society ref. [39]. 
 
The importance of active targeting moieties was also supported by Ou and colleagues, 
where AuNSs conjugated with receptor specific antibodies were used for multiplexed detection 
(Fig.2d-e) of both PD-L1 and epidermal growth factor receptor (EGFR) simultaneously via surface 
enhanced Raman spectroscopy (SERS) in breast cancer in vitro [23] and in vivo [22].  One of the 
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advantages of AuNPs not achievable by other classes of SNPs, is the ability to modulate the shape 
based on simple modifications in synthetic chemistry.  AuNSs are of significant interest for 
imaging due to their unique architecture consisting of a spherical core which acts as the receiver 
antenna and protrusions that concentrate the light on the tips via the nanoantenna effect [40].  This 
phenomenon generates strong electromagnetic fields at the tips of AuNSs resulting in ~109-1012 
enhancements in SERS [41, 42].  In this study, longitudinal SERS in vivo probed the signal of 
Raman reporter molecules, DTNB (1325 cm-1) and pMBA (1580 cm-1), conjugated to AuNSs 
surface corresponding to detection of PD-L1 and EGFR, respectively.  Interestingly, we found 
maximum accumulation of AuNSs in the TME was at 6h post IV delivery in mice, which is distinct 
from spherical NPs >50 nm that accumulate in tumors in 12-24 h indicating shape control is 
important for rapid tumor delivery [21].  Cellular-level resolution ex vivo SERS maps of whole 
tumor lesions indicated heterogeneous distribution of PD-L1 and EGFR (Fig. 2f-g) expected for 
breast tumors, and higher magnification SERS indicated areas within the tumor that were PD-L1-
rich, EGFR-rich, and had both biomarkers.  These latter results are particularly encouraging that 
the combination of shape-controlled SNPs and a powerful imaging modality enable strong 
correlation of in vivo signal with ex vivo analysis necessary to translate these technologies for 
patient stratification of immunotherapies.  
In addition to active targeting, passive accumulation of SNPs can be utilized for 
quantitatively tracking of DCs by intelligent design that preserves their imaging functionality.  Lee 
and colleagues decorated radionuclides (I124/I125) on 20 nm AuNPs through adenine-rich thiolated 
oligonucleotides which allowed a high number of radioisotopes per AuNPs.  Next, they added an 
additional Au shell as a protective layer to provide in vivo stability to the radiolabels and enhance 
longitudinal tracking of DCs via multimodal positron emission tomography (PET) and Cerenkov 
12 
 
luminescence imaging (CLI) [38].  The high sensitivity of whole-body PET complemented the 
high resolution of CLI facilitated accurate molecular contrast in vivo.  Time-course study with 
these SNPs showed DCs migration to draining popliteal lymph nodes (DPLNs) and a synergistic 
correlation of both imaging modalities in AuNPs distribution.  In a follow-up work, Lee and the 
group showed labeling 124I radioisotopes with tannic acid modified AuNPs (Fig.2h) was an 
important design consideration as that reduced the synthesis duration from 50h to ~40 minutes 
[39].  The addition of the protective gold shell, 124I-TA-Au@AuNPs, provided both serum stability 
of the SNPs and radiochemical stability, where most of 124I remained conjugated to the SNPs.  124I-
TA-Au@AuNPs-labeled bone marrow-derived DCs demonstrated long-term reliable PET signal 
at the DPLNs (Fig.2i), indicating the design of AuNPs catalyzes longitudinal tracking of DCs.  The 
size of AuNPs is an important design consideration to accurately track immune cells in vivo as 
discussed in the previous section.  Bhatnagar and coworkers showed with PET imaging a higher 
uptake in T cells of  7 nm PEG functionalized AuNPs conjugated with 64Cu radiolabels relative to 
15 nm AuNPs suggesting careful optimization of design parameters for successful immune cell 
targeting [43].   
 
Superparamagnetic Iron Oxide Nanoparticles (SPIONs) 
SPIONs are FDA-approved T2 contrast agents used in MRI and have been extensively 
applied to track immune cells such as DCs and T cells [44-46].  Tremendous efforts have been 
placed to optimize SPIONs design which include inhibiting oxidation of magnetic cores, reducing 
their aggregation in vivo, and optimizing surface charge for high labeling efficiency.  For example, 
Wu and the group developed biocompatible anionic SPIONs by coating negatively charged block 
copolymer, poly(aspartic acid)‐b‐poly(ε‐caprolactone) (PAsp‐PCL),  used for DCs labeling 
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(Fig.3a-c) [46].  This amphiphilic block polymer is nontoxic and biodegradable and already in 
clinical use.  The size of the polymer coated SPIONs was controlled to ~125 nm and showed high 
T2 relaxivity, and labeled DCs were monitored under a clinical MR imager.  Labeled DCs were 
unaffected in their viability, proliferation, and differentiation capacity demonstrating appropriate 
surface modification of SPIONs is key to accurate monitoring of immune cells.  Xu and coworkers 
adopted a similar approach to improve the biocompatibility of SPIONs with a layer of alkylated 
polyethleneimine and glycerol coating which reduced the positive surface charge of SPIONs [47].  
Further, they labeled the DCs post maturation to prevent changes in their phenotype and observed 
image contrast in vivo and hypointense regions in the central area of draining LNs (Fig.3d).  
Whereas these studies did not use active targeting to direct SPIONs in DCs, an early work by 
Ahrens and colleagues showed CD11c conjugated SPIONs have enhanced uptake in DCs via 
receptor-mediated endocytosis giving rise to 6X higher T2 contrast than non-targeted SPIONs [48].  
Similarly, Baumjohann and the group showed SPIONs conjugated with protamine sulfate, a 
cationic transfection agent that formed molecular complexes via electrostatic interactions, directed 
internalized SPIONs to endosomal compartments in DCs [49].  This resulted in in vivo lymph node 
homing and strong T2 contrast in MRI.  These findings suggest surface modification of SPIONs 
will ultimately govern the translation of SPIONs in monitoring response to immunotherapies in 
patients.  In this effort, Crisci and coworkers labeled porcine monocyte derived DC (MoDCs) with 
SPIONs since domestic pigs share similarities with humans and represent an ideal model for 
immunological studies (Fig.3e) [50].  The authors showed that after a single subcutaneous dose of 






Figure 3. Immunoimaging with superparamagnetic iron oxide nanoparticles and magnetic 
resonance imaging (MRI) (a) Schematic representation of dendritic cell labeling with SPIONs 
for MRI tracking in vivo. (b) Synthesis of block copolymer coated SPIONs and corresponding (c) 
TEM images. (d) MRI images in mouse models in vivo of draining lymph nodes showing enhanced 
contrast from alkylated polyethleneimine and glycerol coated SPIONs. (e) Schametic describing 
the utility of SPIONs in larger animals for labeling porcine monocyte-derived dendritic cells and 
correpsonding MRI image of draining LNs where arrow shows SPIONs accumulation.  (f) 
Schematic of 40 nm SPIONs conjugated with OVA and CpG via PEGylated phospholipid micelles 
for ligand free 67Ga labeling. (g) These SNPs provided effective lymphatic delivery of the vaccines 
and SPECT/CT imaging to track the SNPs and (h) biodistribution expressed as % injected dose 
per gram of tissue. aLN, axillary LN; inLN, inguinal LN; iLN, iliac LN; pLN, popliteal LN; bLN, 
braquial LN. (a) – (c) were adapted with permission from John Wiley and Sons ref. [46], (d) was 
adapted with permission from Elsevier ref. [47], (e) was adapted with permission from Elsevier 
ref. [50], and (f) – (h) were adapted with permission from American Chemical Society ref [51].  
 
In addition to DCs, the versatility of SPIONs has also enabled their use in imaging T cells 
in vivo.  The utility of SPIONs in immunology emerges from an early work, where SPIONs 
modified with NH2 moieties demonstrated enhanced T-cell internalization bypassing the use of 
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transfection agents or electroporation  [52].  These results are not surprising as naturally-existing 
amine molecules, such as histamine and dopamine among others, may directly interact with 
immune cells by modulating their activation [53].  Brewer and coworkers showed that three classes 
of immune cells including CD8+ cytotoxic T cells, regulatory T cells, and myeloid‐derived 
suppressor cells can be monitored after labeling with SPIONs and changes in their migration can 
be measured in vivo following treatment with vaccine‐based immunotherapy [54].  These literature 
evidences suggest SPIONs are highly adaptable SNPs with size and surface tunability, where 
surface functionality drives their ability to hone in a number of immune cells for tracking in vivo.  
Whereas most of these studies have used SPIONs as an MRI contrast agent, a unique work by 
Ruiz-de-Angulo and colleagues indicated that strong MR contrast in vivo typically requires very 
high doses of SPIONs [51].  Therefore, they adopted a unique design consideration, where 40 nm 
iron oxide NPs were coated with PEGylated phospholipid (PEG−PLs) micelles to promote direct 
attachment of Ga3+ ions for in vivo LN targeting (Fig.3f).  The micelles enabled radiolabeling with 
67Ga radioisotopes without macrocyclic chelators for SPECT imaging, and conjugation of the 
model antigen ovalbumin (OVA) or pathogen mimetic CpG without affecting the overall size of 
SPIONs.  SPECT imaging tracked the SNPs in vivo correlating their migration via the lymphatic 
system to reach LNs (Fig.3g).  Their findings suggest SPIONS are well-internalized by antigen 
presenting cells via the endocytotic pathway and reach the LNs draining the site of injection and 
more distal LNs from different anatomical regions of injection (Fig.3h).  The versatility of SPIONs, 
however, allows both MR and nuclear imaging simultaneously, where 64Cu labeled SPIONs 
enabled multimodal PET-MRI for targeted detection of effector T cells in vivo [55].  While the 
authors did not adopt any surface modification, they still achieved rapid T cell labeling, where 
cationic SPIONs migrated to negatively charged cell membranes and transiently permeabilized the 
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membrane barriers with controlled concentrations of dimethyl sulphoxide (DMSO).  These studies 
collectively show that composition of SPIONs controls their imaging functionality but the surface 
charge and chemistry control their biological functionality for immune cell targeting. 
 
Organic Nanoparticles 
In addition to inorganic SNPs, a number of work recently have used organic NPs composed 
of phospholipids, polyglucose, lipoproteins, polypeptide or polymers for labeling TAMs and ICRs.  
Many organic NPs have been FDA approved given their high biocompatibility, colloidal stability, 
ability to encapsulate both hydrophobic and hydrophilic cargos which can be delivered in response 
to external stimuli, and ease of intracellular degradation resulting in rapid in vivo clearance.  
Immunoimaging efforts with organic NPs was demonstrated by Perez-Medina and coworkers who 
incorporated 89Zr radiolabels into high density-lipoproteins (HDLs) either in the protein 
component of HDL (89Zr-Al-HDL) or in the phospholipids (89Zr-PL-HDL) (Fig.4a) to 
longitudinally track TAMs [56].  Both formulations showed sufficient serum stability, high 
radiolabel stability (Fig.4b), and tumor uptake in orthotropic 4T1 mammary tumors as observed in 
PET (Fig.4c).  HDLs were preferably internalized by TAMs relative to monocytes, T cells, and 
cancer cells.  However, the small size of these SNPs, <9 nm, did not allow time-course study of 
TAMs due to rapid renal clearance.  Longer residence in TAMs can be achieved by designing 
larger organic NPs such as liposomes.  Locke and colleagues designed liposomes terminated with 
lipids that targeted mannose receptors (CD206) overexpressed on TAMs (Fig.4d).  Mannose plays 
a pivotal role in clearance of mannose-bearing serum glycoproteins released at sites of 
inflammation [57].  Mannosylated DOTA-encapsulated liposomes were radiolabeled with 64Cu 




Figure 4. Immunoimaging of tumor associated macrophages (TAMs) with organic 
nanoparticles. (a) Structure and composition of 89Zr labelled HDLs and (b) their serum stability. 
Radiotracers were either labelled in the protein components or phospholipids to enable (c) PET/CT 
imaging in mouse models. (d) A schematic diagram of mannose modified liposomes. (e) 64Cu- and 
VT680-labeled macrin were administered to image TAMs at 24h post-injection. Macrin are 
polyglucose NPs with all biodegradable components and L-lysine cross linker. (f) Reconstructed 
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PET/CT showing segmented lung tumors (blue and cyan) and macrin (orange). Representative 
tumors with high macrin uptake (cyan tumors with arrows) were further highlighted in 
corresponding transverse sections. (g) Synthesis of pNPs: PLGA(OVA/ICG); antigen presentation 
(ovalbumin; OVA) and monitoring DCs (indocyanine green; ICG), PLGA(R837/STAT3 siRNA); 
combined immunomodulation with R837 (for activation of TLR7) and STAT3 siRNA (for 
silencing of immunosuppressive genes, STAT3). (h) Scanning electron microscopy (SEM) images 
of PLGA NPs (scale bar 500 nm). (i) Schematic of fluorescent polymeric reporter SNPs where 
both effector and reporter elements were conjugated within the SNPs core. (j) Quantification of 
immunotherapy response to tumor measured with fluorescence intensity ratio between tumor and 
normal tissues at different days after the treatment compared to those measured with IgG-reporter 
SNPs. (k) Schematic showing synthesis of PEI and genipin cross-linked functional OVA SNPs for 
image-guided immunotherapy. (l) Fluorescence imaging of these SNPs showed accumulation in 
the lymph nodes of mice. (m) Combined OVA SNPs showed therapeutic effects with higher MHC-
1, CD86 and CD80 expression in the CD11c+ DCs. (a) – (c) were adapted with permission from 
Society of Nuclear Medicine and Imaging ref. [56], (d) was adapted with permission from Elsevier 
ref. [57], (e) – (f) were adapted with permission from American Chemical Society ref. [58], (g) – 
(h) were adapted with permission from Elsevier ref. [59], and (i) – (j) were adapted with permission 
from National Academy of Sciences of the United States of America ref. [60], (k) – (m) were 
adapted with permission from American Chemical Society ref. [61]. 
 
In addition to lipid based SNPs, Weissleder and Miller demonstrated polyglucose NPs 
(macrin) conjugated with 64Cu were also highly effective in tracking TAMs in vivo with PET 
imaging (Fig.4e) [58].  Macrin differs from previous cross-linked dextran NPs as all components 
are biodegradable, the cross-linker is L-lysine, and biochemical characteristics are optimized to 
avoid rapid renal clearance and maximize accumulation in TAMS.  Macrin exhibited slightly 
negative surface charge (-12 mV), which provided just enough colloidal stability without 
compromising recognition by MPS in vivo.  PET/CT imaging at 24 h post macrin delivery in vivo 
identified macroscopic tumor lesions (Fig.4f), with 10X higher uptake in TAMs relative to tumors.  
This study showed selective uptake in well-defined TAM populations can be achieved with a SNP 
designed to target TAMs and paired with a synergistic immunoimaging toolbox. 
Besides imaging, unlike inorganic SNPs, organic NPs have a unique advantage, where by 
encapsulating a therapeutic entity within the organic core they combine both diagnostic and 
therapeutic components often coined as theranostic.  Such multifunctional SNPs therefore enable 
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highly accurate screening of immune receptors and subsequent image-guided immunotherapies in 
a single clinical procedure.  The most extensively studied theranostic organic NPs for immune 
modulation are composed of poly (lactic-co-glycolic acid) (PLGA), an FDA-approved polymer 
with high biocompatibility and serum stability.  Heo and coworkers showed highly versatile PLGA 
allows to encapsulate model antigen OVA with near-infrared fluorophore indocyanine green (ICG) 
to enable fluorescence guided DC tracking (Fig.4g) [59].  Their unique design approach allowed 
to improve the in vivo targeting efficacy of small interfering RNA (siRNA) and bioavailability of 
immune response modifier (imiquimod, R837) for the activation of DCs by encapsulating both in 
PLGA SNPs.  By using a simple emulsion evaporation method, the authors showed that ~150 nm 
PLGA SNPs (Fig.4h) are an excellent carrier for both hydrophilic and hydrophobic biomolecules 
ideal for immunoimaging and immunotherapies.  Polymer-based SNPs have a distinct advantage 
with an expansive design space and plethora of polymers available for manipulating both the 
surface and core properties of these SNPs.  Kulkarni and coworkers demonstrated this concept 
with a unique biology-inspired engineering of a reporter SNP adopting a two-staged stimuli-
responsive polymer that delivered an immunotherapy payload to the tumor and subsequently 
provided a real time therapy response [60].  The reporter SNPs (Fig.4i) consisted of three 
components: (1) a polymeric backbone from low-molecular weight poly(isobutylene-alt-maleic 
anhydride) (PIMA), (2) an esterase-cleavable prodrug synthesized from an anticancer drug 
(effector element) conjugated to the polymer, and (3) an activatable reporter element which was 
cleavable by caspase-3 to which a FRET pair was conjugated such that cleavage of the amino-acid 
sequence resulted in revival of the fluorescence signal (without that stimuli fluorescence was 
quenched).  Time-course imaging showed strong fluorescence signal for the PD-L1 conjugated 
SNPs relative to IgG control SNPs (Fig.4j).  Flow cytometry confirmed activation of both CD8+ 
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and CD4+ T cells with these SNPs, and significantly higher T cell infiltration in tumors that 
received PD-L1 conjugated SNPs.  A recent work also used organic SNPs to develop a 
nanovaccine with OVA antigen crosslinked with genipin-polyethyleneimine (PEI) and an outer 
OVA layer (Fig.4k), which demonstrated self-fluorescence from the crosslinked polymers [61].  
PEI improves the immune response as an adjuvant of nanovaccine and allows to absorb the outer 
antigen with electrostatic forces.  Genipin does not have an immune function but facilitates 
accurate tracking of the inner antigen with self-fluorescence when cross-linked with PEI without 
the need of extrinsic labels for imaging.  DCs labeled with these OVA SNPs were tracked in vivo 
with multispectral fluorescence imaging to examine their migration to lymph nodes (Fig.4l).  The 
combined OVA nanovaccines induced a stronger DC maturation compared to free OVA and OVA 
SNPs, as demonstrated by significantly increased CD86, CD80, and MHC-I of the CD11c+ cells 
(Fig.4m).  These work collectively demonstrate that organic SNPs are an excellent platform for 
image-guided vaccine delivery and elicit robust and persistent antigen-specific immune responses 
with real-time tracking capabilities.    
 
Conclusions and Future Directions  
In summary, this review summarizes the progress in immunoimaging with three classes of SNPs 
including AuNPs, SPIONs, and organic NPs that have enabled us to track immune cells and detect 
ICRs in vivo, and allowed image-guided immunotherapies in the TME.  Early detection of 
immunomarkers with NP labels will ultimately enable us to identify those who are responders, and 
determine alternative treatment plan for those pre-identified as nonresponders.  Further, we have 
discussed the role of size, shape, surface change, and surface coating of SNPs that determine their 
vascular transport and accumulation in the TME, and ability to induce endothelial leakiness.  
Whereas most of these traditional properties of NPs have been well studied, how NP stiffness 
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(elastic modulus) contributes to cellular uptake remains poorly understood specifically in the 
context of the immune microenvironment.  The elasticity of NPs plays a critical role in NP 
wrapping in the cell membrane and be endocytosed into endosomal vesicles that bud off from the 
cell membrane.  However, the mechanical properties of NPs alone do not direct their preferential 
uptake or evasion in cells; this is also dictated by the cells they interact with.  For example, 
endothelial cells readily uptake soft NPs with low elasticity, whereas macrophages internalize hard 
NPs (>1 MPa) [62] suggesting an additional degree of freedom to tune SNPs uptake in different 
immune cells.  But as discussed previously, these properties are entangled and a systematic study 
is necessary to understand how these parameters can be optimized to design a library of SNPs for 
utility in immunotherapies.  Experimental results will need to be combined with theoretical 
investigations to understand NP wrapping in cell membrane and the corresponding role of NP 
properties and surface ligand density in these processes [63, 64].  Calculations will reveal how 
coupling between membrane bending and stretching in the wrapping process dictates the 
membrane deformation energy, and how the SNP design coupled with the type of immune cell 
will drive the rate, and number of SNPs uptake in the immune TME. 
We envision the importance of SNPs in the immunotherapy landscape will ultimately be 
interfaced with emerging areas such as tracking circulating immune cells which are associated 
with tumor location and differentiation [65], and hybrids of cancer cells fused with immune cells 
that potentiate tumor heterogeneity and stage [66, 67].  Further, single cell tracking of NP-labeled 
immune cells will reveal crosstalk between the different immune cells, and highlight signaling 
pathways within individual immune cells that are suppressed in the TME [68-71].  These 
fundamental understanding will ultimately result in novel vaccines with higher clinical efficacy.  
Image-guided approaches with SNPs could be extended to other therapeutic modalities, where 
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immunotherapies are combined with photothermal [72-74], photodynamic [75], and 
chemotherapies [76, 77] to induce adaptive immune responses and stimulate immunological 
memory.  Therefore, SNPs with multiple functionalities can ultimately advance the drug 
development pipeline and significantly reduce the cost involved in translating these immunoagents 
from laboratory to human applications. 
 
Outstanding Questions 
(1) What design parameters need to be considered to synthesize smart nanoparticles that accurately 
monitor dynamic changes in immunomarkers during the course of immunotherapy? 
(2) What are the restrictions and challenges that are currently hindering clinical translation of smart 
nanoparticles? 
(3) What physicochemical properties of smart nanoparticles are most important to direct them to 
tumor-associated macrophages relative to macrophages resident in liver and spleen? 
(4) What fundamental studies can be pursued with smart nanoparticles-labeled immune cells to 
reveal crosstalk between different immune cells in cancer pathogenesis? 
(5) Does nanoparticle induced endothelial cell leakiness have a role in immunotherapies reaching 












Table 1. Imaging immune cells and immunomarkers with smart nanoparticles utilizing a 
broad array of clinical and preclinical imaging modalities to guide immunotherapies in 
cancer and other diseases.    
 
Target Agent Imaging 
modality 
Summary Ref. 
T cells Gold nanoparticle 
(AuNP) 
CT Engineered T-cells that were transduced to 
express melanoma-specific T-cell receptors 
were loaded with AuNPs as a CT contrast 
agent.  Correlated CT imaging with live 
fluorescence imaging revealed the accuracy of 






MRI CLIO-HDs allowed to track T cells and MRI 
imaging showed the recruitment of CLIO-
HD-labeled OVA-specific CD8+ T cells to 
intact tumors in vivo.  Furthermore, these 
CD8+ T cells were recruited in a 










SPIONs conjugated with 64Cu were used for 
multimodal imaging to detect accumulation of 
labeled-T cells.  MRI provided high-
resolution anatomically correlated images and 








CAR+ T cells in vivo biodistribution was 
tracked through labeling T cells with 64Cu-






MRI USPIO SNPs conjugated to the HIV tat 
peptide were used to label both murine and 
human CD4+ T cells, which showed 
suppressive responses and were tracked with 





MRI Fluorescent labeled iron-oxide SNPs were 
used to label rat and human T-cells and were 
used to detect immune cells at the allograft 









OVA antigen encapsulated and fluorescently 
labeled pLHMGA SNPs showed sustained 
release of antigen in vitro and antigen cross-
presentation by DCs to antigen-specific T 
cells.  Fluorescence imaging showed the 
relocation of both antigen and SNPs from the 




FLI Iron oxide SNPs were coated with 
polyaspartamide derivatives to enhance their 
biocompatibility, stability, and fluorescence 
detection.  The polymer coating allowed 
efficient binding to the surface of CD4+ T 




Dendritic cells Upconversion 
nanoparticle 
(UCNP) 
UCL Antigen-loaded UCSNPs were used to label 
DCs, which were accurately tracked by in 
vivo UCL imaging.  Antigen-specific immune 






FLI Chitosan nanoparticles with surface mannose 
were loaded with tumor cell lysate generated 
from B16 melanoma cells.  Fluorescence 






FLI A combined nanovaccine with OVA and 
labeled with the rhodamine B was tracked in 
vitro and in vivo with multispectral 
fluorescence imaging.  The nanovaccine 
induced antigen-specific CD4+ and CD8+ T 






MRI, PL SPIO core/ZnO shell SNPs were used as 
antigen delivery vehicles.  Tumor antigens 
(CEA) were immobilized onto core-shell 
nanoparticles.  PL of the ZnO allowed the 
SNPs to be examined using confocal 
microscopy.  In vivo MRI revealed that the 









RIe-AuNPs showed high radiosensitivity and 
excellent in vivo stability, which enabled dual 
nuclear and optical imaging.  PET/CT and 
CLI were utilized to track migration of RIe-
AuNPs labeled-DC to draining lymph nodes. 
[38] 
Superparamagneti
c iron oxide 
(SPIO) 
MRI SPIO-labeled DCs were injected intranodally 
in melanoma patients under ultrasound 
guidance.  MRI allowed verification of the 
accurate delivery and monitoring of inter- and 
intra-nodal cell migration patterns.  
[86] 
Radioiodine-124-




PET/CT 124I-TA-Au@AuNPs with excellent 
radiochemical stability and biocompatibility 
were used for DC labeling and in vivo 




c iron oxide 
(SPIO) 
MRI SPIO-labeled DCs were tracked in vivo using 
cellular MRI.  Labeling DCs with SPIO had 
no significant effect on DC viability, 






FLI QDs were selectively taken up by DCs in 
vivo, and could be used as a fluorescent 
marker for tracking of DC migration.  
Moreover, antigen-conjugated QDs enhanced 










IONPs coated with PEGylated phospholipid 
(PEG-PLs) micelles enabled radiolabeling 
with Ga3+ ions suitable for 
SPECT(67Ga)/PET(67Ga) imaging, and 
conjugation of the model antigen ovalbumin 
(OVA) or pathogen mimetic CpG without 
affecting the overall size of IONPs.  SPECT 
imaging tracked the IONPs in vivo correlating 






FLI PLGA NPs containing model antigen OVA 
and near-infrared enabled fluorescence 
imaging for DC tracking.  These nanoparticles 
were taken up efficiently by DCs. 
[59] 
Macrophages Superparamagneti
c iron oxide 
(SPIO) 
MRI SPIO nanoparticles-enhanced MRI imaging 
was used to detect TAMs.  Folate-engrafted 





PET/CT 89Zr-labeled DNPs were used as probe for 
PET/CT imaging in a colon carcinoma model.  
89Zr-labeled DNP were biocompatible and 
accumulated specifically in tissue resident 











PET High-density lipoprotein loaded with 89Zr was 
used to track TAMs in a breast cancer model 





PET MAN-LIPs were loaded with 64Cu to allow 





PET 64Cu-labeled polyglucose nanoparticles 
(macrin) enabled in vivo PET imaging of 
TAMs.  PET studies were complemented with 
confocal fluorescence microscope and flow 
cytometry.  The studies confirmed macrin was 
predominantly uptake by TAMs. 
[58] 
B cells Superparamagneti




Dextran-coated SPIOs were used for B cells 
labeling and tracking.  SPIO-labeled B cells 
were injected into mice for in vivo MRI and 
NIR fluorescence imaging to study B cell 
trafficking and distribution. 
[92] 
PD-L1 Gold nanostar 
(AuNS) 
SERS AuNS conjugated with both antibodies and 
Raman tags were used to diagnose PD-L1 and 
EGFR in breast cancer tumors in vivo using 







CT AuNPs served as contrast agents for CT 
imaging, and enabled noninvasive, 
longitudinal tracking of immunomodulators in 
tumors.  CT imaging with PDL1-AuNPs 
allowed early prediction of checkpoint 




FLI Reporter nanoparticles allowed simultaneous 
delivery of therapeutic agents and real-time 











NIR FLI The CyAL5.5-FH superparamagnetic and 
fluorescent nanoparticles were used to 
understand immune cell function and TME 
using fluorescence imaging by probing 
MDSCs. 
[93] 
CD44v6 SPION coated 
with oleic acid- 
carboxymethyl 
dextran (CMD) 
and antiCD44v6  
MRI SPIONs were coated with OA and CMD 
conjugated with antiCD44v6 antibody to 
improve saturation magnetization, and to 
enhance MRI detection of lung cancer 
metastasis. 
[94] 
a. Acronyms for imaging modalities: CT = computed tomography; MRI = magnetic resonance 
imaging; PET = positron emission tomography; PL= Photoluminescence; NIR = near-infrared; 
FLI = fluorescence imaging; UCL = upconversion luminescence; CLI = Cerenkov 
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